13F reference period
Q2 2026
Security Snapshot
Arbutus Biopharma Corp - Common Shares (ABUS) Institutional Ownership
CUSIP: 03879J100
13F Institutional Holders and Ownership History from Q2 2015 to Q3 2026
Institutions Reporting
176
Shares (Excl. Options)
140,611,167
Price
$4.80
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares
- Symbol
- ABUS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 140,611,167
- Total 13F value
- $674,862,301
- Portfolio coverage rank
- 0%
- Share change
- +1,104,689
- Value change
- +$6,561,212
- Number of holders
- 176
- Shares outstanding
- 153,136,951
- SEC-reported price per share
- $4.78
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ABUS - Arbutus Biopharma Corp - Common Shares is tracked under CUSIP 03879J100.
- 176 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 166 to 176 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $625,429,886 to $674,862,301.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 176 institutions filings for Q2 2026.
Security key
03879J100
13F reference period
Q2 2026
13F holders
176
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
ABUS full holder history
Arbutus Biopharma Corp SEC filings
Arbutus Biopharma Corp company facts
Arbutus Biopharma Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03879J100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ABUS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 20% | -4.8% | $152,986,004 | -$45,913,001 | 29,880,079 | -23% | Roivant Sciences Ltd. | 01 Oct 2026 |
| MORGAN STANLEY | 12% | +38% | $89,303,344 | +$6,191,582 | 18,682,708 | +7.4% | Morgan Stanley | 30 Sep 2026 |
| Two Seas Capital LP | 9.4% | +41% | $79,797,435 | +$25,664,056 | 18,557,543 | +47% | Two Seas Capital LP | 31 Mar 2026 |
| Whitefort Capital Management, LP | 8% | 0% | $73,759,199 | 15,794,261 | 0% | Whitefort Capital Master Fund, LP | 04 Sep 2026 |
As of 30 Jun 2026, 176 institutional investors reported holding 140,611,167 shares of Arbutus Biopharma Corp - Common Shares (ABUS). This represents 92% of the company’s total 153,136,951 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
82%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Two Seas Capital LP | 12% | 19,095,583 | +2.9% | 3.5% | $91,658,798 |
| MORGAN STANLEY | 12% | 17,698,305 | -32% | 0% | $84,951,868 |
| Whitefort Capital Management, LP | 10% | 15,794,261 | +5.8% | 19% | $75,812,453 |
| BlackRock, Inc. | 9% | 13,766,071 | +6.2% | 0% | $66,077,140 |
| STATE STREET CORP | 5.1% | 7,869,179 | +24% | 0% | $37,772,059 |
| Rubric Capital Management LP | 4.9% | 7,532,937 | +14% | 0.33% | $36,158,098 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6% | 7,010,679 | +4.8% | 0% | $33,651,259 |
| BARCLAYS PLC | 2.7% | 4,207,914 | -2.5% | 0.01% | $20,197,987 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 4,117,691 | +9.2% | 0% | $19,769,043 |
| GOLDMAN SACHS GROUP INC | 2.3% | 3,506,802 | +219% | 0% | $16,832,650 |
| BANK OF AMERICA CORP /DE/ | 1.7% | 2,646,197 | +57% | 0% | $12,701,745 |
| BlackBarn Capital Partners LP | 1.6% | 2,500,000 | 0% | 3% | $12,000,000 |
| Legal & General Group Plc | 1.6% | 2,466,127 | +2.7% | 0% | $11,837,409 |
| Woodline Partners LP | 1.5% | 2,281,856 | +14% | 0.03% | $10,952,909 |
| Jefferies Financial Group Inc. | 1.1% | 1,711,672 | -9.6% | 0.08% | $8,216,026 |
| NOMURA HOLDINGS INC | 1.1% | 1,637,081 | 0.04% | $7,857,989 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1% | 1,541,458 | +11% | 0% | $7,398,998 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.93% | 1,431,218 | +2.1% | 0% | $6,869,846 |
| NORTHERN TRUST CORP | 0.93% | 1,419,024 | +11% | 0% | $6,811,315 |
| OSAIC HOLDINGS, INC. | 0.88% | 1,347,866 | -0.02% | 0.01% | $6,469,756 |
| ADAR1 Capital Management, LLC | 0.83% | 1,268,147 | -60% | 0.29% | $6,087,106 |
| Deltroit Asset Management (UK) LLP | 0.78% | 1,200,000 | +50% | 0.94% | $5,760,000 |
| VANGUARD FIDUCIARY TRUST CO | 0.74% | 1,135,362 | +6.8% | 0% | $5,449,738 |
| CITIGROUP INC | 0.57% | 879,237 | -2.1% | 0% | $4,220,338 |
| BANK OF MONTREAL /CAN/ | 0.51% | 777,938 | -0.62% | 0% | $3,734,102 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
46
Headline period
Q2 2026
Rows shown
1-25 of 46
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 9,196,437 | $43,957,889 | -$49,021,423 | $4.78 | 20 |
| 2026 Q2 | 140,611,167 | $674,862,301 | +$6,561,212 | $4.80 | 176 |
| 2026 Q1 | 138,984,840 | $625,429,886 | +$75,257,846 | $4.50 | 166 |
| 2025 Q4 | 122,028,178 | $586,934,773 | +$19,507,202 | $4.81 | 173 |
| 2025 Q3 | 118,168,575 | $536,370,600 | +$2,487,933 | $4.54 | 166 |
| 2025 Q2 | 118,112,086 | $364,964,865 | +$19,645,984 | $3.09 | 162 |
| 2025 Q1 | 111,778,063 | $390,115,968 | +$29,488,807 | $3.49 | 167 |
| 2024 Q4 | 104,075,822 | $340,339,884 | +$3,767,856 | $3.27 | 153 |
| 2024 Q3 | 101,100,254 | $389,229,670 | +$15,557,626 | $3.85 | 143 |
| 2024 Q2 | 96,687,257 | $298,333,597 | +$40,873,896 | $3.09 | 129 |
| 2024 Q1 | 83,370,717 | $215,132,214 | +$11,550,835 | $2.58 | 118 |
| 2023 Q4 | 78,913,089 | $197,297,266 | +$10,900,831 | $2.50 | 110 |
| 2023 Q3 | 70,841,695 | $143,815,507 | +$8,057,833 | $2.03 | 96 |
| 2023 Q2 | 66,235,432 | $152,407,843 | +$7,387,882 | $2.30 | 109 |
| 2023 Q1 | 62,470,799 | $189,264,221 | +$26,478,755 | $3.03 | 120 |
| 2022 Q4 | 54,227,682 | $126,382,359 | +$17,821,528 | $2.33 | 110 |
| 2022 Q3 | 46,620,587 | $89,144,270 | -$921,936 | $1.91 | 121 |
| 2022 Q2 | 35,268 | $93,574 | -$3,027,847 | $2.18 | 11 |
| 2022 Q1 | 43,886,769 | $130,608,351 | +$4,239,945 | $2.98 | 111 |
| 2021 Q4 | 39,679,851 | $154,349,574 | +$14,066,593 | $3.89 | 114 |
| 2021 Q3 | 34,872,896 | $149,655,492 | +$26,301,612 | $4.29 | 96 |
| 2021 Q2 | 28,908,795 | $87,633,862 | +$7,803,555 | $3.03 | 83 |
| 2021 Q1 | 25,991,001 | $86,467,063 | +$11,894,875 | $3.33 | 88 |
| 2020 Q4 | 21,915,953 | $77,813,914 | -$4,704,362 | $3.55 | 72 |
| 2020 Q3 | 24,142,348 | $75,528,504 | +$7,771,699 | $3.13 | 60 |